Arcutis Biotherapeutics Inc. (NASDAQ:ARQT) finished Friday with a subtraction of -$0.32 to close at $8.96, a downside of -3.45 percent. An average of 813,380 shares of common stock have been traded in the last five days. There was a fall of -$0.87 in the past week, and it reached a new high 4 times over the past 12 months. The last 20 days have seen an average of 764,690 shares traded, while the 50-day average volume stands at 1,074,866.
ARQT stock has decreased by -4.58% in the last month. The company shares reached their 1-month lowest point of $8.82 on 08/11/23. With the stock rallying to its 52-week high on 03/01/23, shares of the company touched a low of $7.25 and a high of $27.40 in 52 weeks. It has reached a new high 10 times so far this year and lost -39.46% or -$5.84 in price. In spite of this, the price is down -67.30% from the 52-week high.
Insider Transactions
ARQT stock investors should be aware that Arcutis Biotherapeutics Inc. (ARQT) stock had its last reported insider trading activity 73 days ago on May 31. In this transaction, the insider spent $14,278. Director, Welgus Howard G., disposed of 8,500 shares at a price of $13.97 on Apr 17. The insider now owns more than $118,728 worth of shares. Prior to that, Director Welgus Howard G. went on to Sale 8,500 shares at $12.01 each on Apr 06. An amount of $102,085 was transacted.
Valuation Metrics
Arcutis Biotherapeutics Inc. (ARQT) stock’s beta is 0.63. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 87.16, the price-to-book (PB) ratio at 3.93.
Financial Health
The quick ratio of Arcutis Biotherapeutics Inc. for the recent quarter was 9.70, and the current ratio was 9.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.42 and a total debt to equity ratio of 1.42 for the recent quarter. Arcutis Biotherapeutics Inc.’s EBITDA margin is -8149.05%. Its gross profit as reported stood at $2.93 million compared to revenue of $3.69 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Arcutis Biotherapeutics Inc.’s return on assets was -79.90%.
Earnings Surprise
For the recent quarter, Arcutis Biotherapeutics Inc. had $163.56 million in cash and short-term investments compared to $199.77 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$70.99 million in the quarter, while revenues were grew 5.04%. Shareholders own equity worth $61.65 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Arcutis Biotherapeutics Inc. (ARQT) price momentum. RSI 9-day as of the close on 11 August was 31.58%, suggesting the stock is Neutral, with historical volatility in this time frame at 60.24%.
As of today, ARQT’s price is $9.41 -8.85% or -$0.87 from its 5-day moving average. ARQT is currently trading -5.08% lower than its 20-day SMA and -22.56% lower than its 100-day SMA. However, the stock’s current price level is +19.31% above the SMA50 and -46.12% below the SMA200.
The stochastic %K and %D were 8.03% and 13.92%, respectively, and the average true range (ATR) was 0.71. With the 14-day stochastic at 6.47% and the average true range at 0.70, the RSI (14) stands at 38.79%. The stock has reached -0.55 on the 9-day MACD Oscillator while the 14-day reading was at -0.83.
Analyst Ratings
Needham launched coverage on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT) in its analyst report released on September 07, 2022. The firm assigned the stock a Buy rating. The consensus rating for Arcutis Biotherapeutics Inc. (ARQT) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ARQT, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.
What is ARQT’s price target for the next 12 months?
Analysts predict a range of price targets between $22.00 and $57.00, with a median target of $44.50. Taking a look at these predictions, the average price target given by analysts for Arcutis Biotherapeutics Inc. (ARQT) stock is $41.88.
